Making more quality medicines in more places
To strengthen the medicines supply chain and help guard against potential shortages that can impact patient care, more quality medicines need to be made in more places. Beyond supporting innovation in medicines themselves, facilitating adoption of advanced manufacturing technology (AMT) like pharmaceutical continuous manufacturing (PCM) is an essential part of the solution.
Policy considerations: Harnessing pharmaceutical continuous manufacturing for a more resilient supply chain
At USP, we’re collaborating with our expert volunteers and other stakeholders across the healthcare ecosystem to reduce barriers to adoption of advanced manufacturing technology and pharmaceutical continuous manufacturing by:
Addressing knowledge gaps,
Working with partners to certify and validate related manufacturing processes,
Weighing the potential for incentives, investments, and other policy reforms, and
Exploring where there is a need and opportunity to develop new guidelines, best practices, and quality standards to help set expectations for quality, speed approvals, and support public trust.
Learn about USP’s collaboration with Phlow Corp to support PCM adoption through our efforts to certify and validate related manufacturing processes.
USP standards and related programs support quality, innovation & supply chain resilience.
Advanced manufacturing education
- Improving the Supply Chain with Continuous Manufacturing: Pharmaceutical Solid Dosage Forms (USP and Rutgers University)
- Four-Day Series on Quality of 3D Printing of Medicines and Supplements (USP and International Association for Pharmaceutical Technology)
- Webinar Series on Pharmaceutical 3D-Printing (USP and Purdue University)